Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriatic arthritis

FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

Michele B. Kaufman, PharmD, BCGP  |  November 20, 2019

The FDA has limited the package size of some over-the-counter loperamide products to prevent its potential misuse and abuse…

Filed under:Biologics/DMARDsDrug Updates Tagged with:abuseBAT2506FDAGolimumabloperamideU.S. Food and Drug Administration (FDA)

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2019

The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…

Filed under:Drug Updates Tagged with:PsoriasisrisankizumabScottish Medicines Consortiumsecukinumab

Case Report: A Patient on Apremilast Develops Streptococcus Salivarius

Stephanie Kydd Dondero, DO, & Barry Waters, MD  |  October 18, 2019

Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immuno­modulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine mono­phosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…

Filed under:Conditions Tagged with:apremilastcase reportimmunosuppressive drugsStreptococcus salivarius

‘Cookbook Medicine’ Is More Popular Than Ever (& That’s a Good Thing)

Paula Marchetta, MD, MBA  |  October 18, 2019

In 2004, the British Medical Journal published an article titled, “Resisting Cookbook Medicine,” which looked askance at the “routine use of pre­determined directives” in clinical practice because it reduced doctors to practicing so-called cookbook medicine and eroded the art of medicine.1 Fast forward 15 years, and we find our appetite for “predetermined directives”—what we now…

Filed under:President's Perspective Tagged with:cookbook medicineDevelopment and Evaluation (GRADE)evidence-based guidelinesGrading of RecommendationsGuidelines

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

Mary Choy, PharmD, BCGP, FASHP  |  October 14, 2019

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:GoutGout Resource Center

Imagining a Life Free from the Pain of Ankylosing Spondylitis

Lara C. Pullen, PhD  |  September 30, 2019

Dan Reynolds, the lead singer of the Grammy award-winning band Imagine Dragons, has partnered with Novartis to increase awareness of ankylosing spondylitis.

Filed under:Axial SpondyloarthritisConditionsPsoriatic Arthritis Tagged with:Ankylosing SpondylitisMonster Pain in the ASNovartisplaque psoriasisPsoriatic Arthritissecukinumab

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR  |  September 26, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondyloarthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisUveitis

FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  September 23, 2019

Data from two phase 3 studies were used to support the FDA’s approval of ixekizumab for adults with ankylosing spondylitis…

Filed under:Axial SpondyloarthritisDrug Updates Tagged with:Ankylosing SpondylitisFDAixekizumabU.S. Food and Drug Administration (FDA)

Case Report: Does a Rapid-Onset Neck Mass Have Rheumatic Origins?

Tej Bhavsar, MD, & Nancy Joste, MD  |  September 17, 2019

A 54-year-old African American man arrived at the emergency department with the acute onset of a tender mass on the left side of his neck. It had been getting progressively larger for the preceding two days. History & Examination His history included chronic right hip osteoarthritis with two surgeries performed five years prior. At his…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:AmyloidosisCancercase report

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

Michele B. Kaufman, PharmD, BCGP  |  September 16, 2019

Hadlima (adalimumab-bwwd), which is biosimilar to adalimumab, is now FDA approved to treat multiple autoimmune diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumab-bwwdFDAFDA approvalHadlimaU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 63
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences